Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $34.1667.

Several analysts have issued reports on the company. TD Cowen began coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Finally, Chardan Capital restated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th.

Dyne Therapeutics Stock Up 5.9%

Shares of Dyne Therapeutics stock opened at $23.07 on Friday. The company has a market capitalization of $3.81 billion, a P/E ratio of -7.16 and a beta of 1.06. The business’s fifty day moving average price is $18.63 and its two-hundred day moving average price is $18.16. Dyne Therapeutics has a 1-year low of $8.06 and a 1-year high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the firm earned ($1.05) EPS. As a group, research analysts forecast that Dyne Therapeutics will post -3.02 EPS for the current year.

Insider Activity

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian S. Posner bought 2,000 shares of Dyne Therapeutics stock in a transaction dated Monday, June 8th. The stock was purchased at an average price of $16.94 per share, for a total transaction of $33,880.00. Following the purchase, the director directly owned 24,500 shares in the company, valued at $415,030. This represents a 8.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 9,000 shares of company stock worth $156,800 and have sold 2,334,279 shares worth $46,221,906. 9.46% of the stock is owned by company insiders.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in shares of Dyne Therapeutics by 9.0% in the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after acquiring an additional 278,466 shares in the last quarter. Aberdeen Group plc boosted its position in shares of Dyne Therapeutics by 99.0% during the fourth quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock worth $21,675,000 after buying an additional 551,412 shares during the period. SG Americas Securities LLC bought a new position in shares of Dyne Therapeutics during the fourth quarter worth about $5,191,000. Clearbridge Investments LLC bought a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $7,976,000. Finally, Fisher Asset Management LLC bought a new position in Dyne Therapeutics in the fourth quarter valued at $4,891,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.